STOCK TITAN

Medicus Pharma Ltd. (MDCX) Form 4 Filings

MDCX NASDAQ

Here are the Form 4 insider transactions from Medicus Pharma Ltd. (MDCX) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.

A Form 4 covers the transactions officers, directors and large holders report, so if you follow MDCX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MDCX filings page.

Rhea-AI Summary

Medicus Pharma Ltd. reported an equity award for its President and CFO, Carolyn F. Bonner. On December 16, 2025, she received a stock option grant covering 75,000 common shares at an exercise price of $1.8 per share. These options are scheduled to vest quarterly in four equal installments over one year, meaning portions of the grant become exercisable every quarter during that period.

After this grant, she held 75,000 derivative securities directly, all tied to the company’s common shares. This type of award is a common form of equity-based compensation that links an executive’s potential future gains to the company’s share performance.

Rhea-AI Summary

Medicus Pharma Ltd. (MDCX) reported an equity award to its Chief Executive Officer and director, Raza Bokhari. On December 16, 2025, he received a stock option covering 125,000 common shares with an exercise price of $1.8 per share and an expiration date of December 16, 2030. The option is scheduled to vest quarterly in four equal installments over one year, meaning the award becomes fully vested after that period if service conditions are met. Following the grant, 125,000 derivative securities are shown as beneficially owned with direct ownership.

Rhea-AI Summary

Medicus Pharma Ltd. reported a new stock option grant to a director. On December 16, 2025, the director received a stock option to buy 25,000 common shares of Medicus Pharma at an exercise price of $1.8 per share, expiring on December 16, 2030.

The option is scheduled to vest quarterly in four equal installments over one year, aligning the director’s potential equity ownership with short-term company performance. Following this grant, the director beneficially owns 25,000 derivative securities, held as a direct ownership position.